Login
Bellicum Pharmaceuticals NASDAQ: BLCM
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders
| Name | Bellicum Pharmaceuticals |
| Ticker | BLCM |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
3.41
2.71 / 9.03 |
| Momentum | Sharp Down |
| Market cap | 17 M |
| 1Y Total Return |
-48.10%
Weak |
| 1Y Volatility |
107.52%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders
Details
| Ticker | BLCM |
| Name | Bellicum Pharmaceuticals |
| ISIN | US0794811077 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 4/13/21
| Close Price | 3.41 |
| 52W Low/High | 2.71 / 9.03 |
| Market cap | 17 M |
| 1Y Total Return |
-48.10%
Weak |
| 1Y Volatility |
107.52%
High Risk |
| Beta | 1.97 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -1,544.4% |
| Cash from Op. / Cur. Liabilities | -2.29 |
| Diluted Earnings / Share | -1.34 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 39.3 |
| Price / Book | -7.9 |
| Price / CF | -0.3 |
| Current Ratio | 1.6 |
| Cur.Liabilities / Tot.Liabilities | 1.0 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
1
|
7
|
1
|
0
|
0
|
0
|
|
| Gross Profit |
1
|
7
|
1
|
0
|
0
|
0
|
|
| R&D |
39
|
65
|
72
|
66
|
51
|
34
|
|
| EBITDA |
-3
|
-100
|
-87
|
-85
|
-65
|
-47
|
|
| Operating Income |
-55
|
-87
|
-95
|
-87
|
-68
|
-49
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
6
|
5
|
4
|
3
|
3
|
3
|
|
| EPS exc. Extra |
-1.34
|
-24.01
|
-24.37
|
-28.90
|
-25.70
|
-18.40
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
41
|
116
|
122
|
136
|
132
|
160
|
|
| Cash, Eq & Invt ShortTerm |
37
|
94
|
93
|
105
|
113
|
94
|
|
| Total Current Assets |
39
|
112
|
95
|
102
|
106
|
97
|
|
| Total Non-Current Assets |
1
|
4
|
26
|
34
|
26
|
64
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
25
|
121
|
53
|
51
|
35
|
8
|
|
| Total Current Liabilities |
25
|
94
|
16
|
12
|
15
|
7
|
|
| Long Term Debt |
0
|
27
|
37
|
39
|
20
|
1
|
|
| Shareholder equity |
-2
|
-26
|
68
|
85
|
97
|
152
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-57
|
-78
|
-75
|
-73
|
-50
|
-36
|
|
| Depreciation |
2
|
9
|
7
|
4
|
2
|
1
|
|
| Cash from Investing |
14
|
49
|
10
|
-3
|
2
|
-86
|
|
| Capex |
14
|
1
|
2
|
12
|
7
|
5
|
|
| Cash from Financing |
-14
|
74
|
68
|
78
|
21
|
1
|
|
| Stock Issued |
23
|
51
|
68
|
66
|
1
|
1
|
|
| Debt (LT) Issued |
-37
|
0
|
0
|
12
|
20
|
0
|
|
| Free Cash Flow |
-85
|
27
|
-75
|
-89
|
-111
|
-73
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
1.6
|
1.2
|
6.0
|
8.4
|
7.0
|
13.0
|
|
| Financial Leverage D/E |
-
|
-
|
0.53
|
0.41
|
0.21
|
0.00
|
|
| Return on Capital Avg |
-
|
-
|
-133.7%
|
-115.6%
|
-86.0%
|
-116.6%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available